Drugs Made In America Acquisition (NASDAQ:DMAA) Shares Down 0% – What’s Next?

Shares of Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) traded down 0% during mid-day trading on Friday . The stock traded as low as $10.51 and last traded at $10.5150. 25 shares traded hands during trading, a decline of 100% from the average session volume of 68,320 shares. The stock had previously closed at $10.52.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Drugs Made In America Acquisition in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Drugs Made In America Acquisition Stock Performance

The company’s 50 day moving average price is $10.47 and its 200-day moving average price is $10.39.

Hedge Funds Weigh In On Drugs Made In America Acquisition

Hedge funds have recently bought and sold shares of the company. Quarry LP bought a new position in Drugs Made In America Acquisition during the third quarter worth $161,000. Sandia Investment Management LP bought a new position in Drugs Made In America Acquisition during the third quarter worth $161,000. Lineage Point Capital LP bought a new position in Drugs Made In America Acquisition during the fourth quarter worth $330,000. JPMorgan Chase & Co. bought a new position in Drugs Made In America Acquisition during the third quarter worth $1,024,000. Finally, Shaolin Capital Management LLC bought a new position in Drugs Made In America Acquisition during the second quarter worth $1,020,000.

About Drugs Made In America Acquisition

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.